Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease. (20th December 2019)

• Record Type: Journal Article
• Authors: Piccinni, Rosangela; Rodrigues, Susana G.; Montani, Matteo; Murgia, Giuseppe; Delgado, Maria G.; Casu, Stefania; Stirnimann, Guido; Semmo, Nasser; De Gottardi, Andrea; Dufour, Jean‐François; Berzigotti, Annalisa
• Is Part Of: Liver international. Volume 40:Number 5(2020)
• Page Start: 1151
• Page End: 1158
• Publication Date: 2019-12-20
• Subjects: cirrhosis -- liver biopsy -- liver stiffness -- NASH -- steatosis; Liver -- Periodicals; Liver -- Diseases -- Periodicals; 616.362
• DOI: 10.1111/liv.14325
• Languages: English
• ISSNs: 1478-3223

Abstract

Abstract: Background & Aims: Controlled attenuation parameter (CAP) for steatosis assessment has not been validated in compensated advanced chronic liver disease compensated advanced chronic liver disease (cACLD). We primarily aimed at assessing the accuracy of CAP for the diagnosis and quantification of steatosis in cACLD. Secondary aim: to assess the validity of non‐invasive criteria for cACLD according to liver stiffness measurement (LSM). Methods: This is a single‐centre retrospective study including patients with cACLD defined as LSM ≥10 kPa, CAP measurement and liver biopsy (reference standard for steatosis and fibrosis) observed in 06/2015‐06/2017. Steatosis was graded as S0 (<5%), S1 (5%‐32%), S2 (33%‐66%) and S3 (>66%). The diagnostic performance of CAP for any grade of steatosis and for high‐grade steatosis (≥S2) was studied. Results: Among 461 consecutive patients, 111 with LSM‐based diagnosis of cACLD were included (63% male, median age 55 years, median body mass index 28.1 Kg/m 2, aetiology: 32% non‐alcoholic fatty liver disease/non‐alcoholic steatohepatitis, 32% alcohol or viral + metabolic syndrome, 15% viral, 6% autoimmune, 4% alcohol, 11% others). Median LSM and CAP were 16.1 kPa and 277 dB/m respectively. On liver biopsy, steatosis was found in 88/111 patients (79%); 44 patients (43 with metabolic syndrome) had high‐grade steatosis. CAP was accurate in identifying any grade of steatosis (area under the receiving operating characteristic curves 0.847; 95% CI 0.767‐0.926, P < .0001), and ≥S2 steatosis (0.860; 95% CI 0.788‐0.932, P < .0001). CAP performed similarly in patients with CAP‐ interquartile range (IQR) ≥ or <40 dB/m. Conclusions: Steatosis is frequent in patients with cACLD and metabolic syndrome. CAP diagnostic accuracy for any steatosis and high‐grade steatosis is good in this population. A CAP‐IQR ≥40 dB/m does not impair CAP diagnostic accuracy in cACLD.